|Day Low/High||9.43 / 9.80|
|52 Wk Low/High||4.83 / 23.59|
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
Even concerns about a possible Fed rate hike do not appear to be affecting traders.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Karyopharm Therapeutics Inc , where a total volume of 2,316 contracts has been traded thus far today, a contract volume which is representative of approximately 231,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 168.7% of KPTI's average daily trading volume over the past month, of 137,260 shares.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Conference Call Scheduled for Thursday, August 4, 2016 at 8:30 a.m. ET
Investors considering a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $7.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $5 strike, which has a bid at the time of this writing of 60 cents.
First-in-class Immunometabolic Modulator, PAK4/NAMPT Inhibitor, to be Evaluated in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Stocks with insider trader activity include TRUP, KPTI and FCBC
Stocks with insider trader activity include KPTI, CPIX and LB
Stocks with insider trader activity include W, KPTI and GVP
- Data Describes Early Activity of Selinexor in Combination with Standard of Care Agents for Treatment of Relapsed/Refractory Multiple Myeloma -
Single-agent Selinexor in Recurrent Glioblastoma and Selinexor Combination Data in Multiple Myeloma
Conference Call Scheduled for Monday, May 9, 2016 at 8:30 a.m. ET
Preclinical data on KPT-350, Karyopharm's Selective Inhibitor of Nuclear Export (SINE™) compound, presented at the 2016 American Academy of Neurology Annual Meeting